Back

Relationship between cumulative exposure to systemic inflammation response index and risk of all-cause mortality in middle-aged and older adults with cardiovascular-kidney-metabolic syndrome stage 0–2

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk assessment Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Rongchong Huang

Beijing Friendship Hospital, Capital Medical University, Beijing (China)

5 More presentations in this session

Presentation thumbnail
Distribution and temporal trends of predicted ten-year and lifetime atherosclerotic cardiovascular disease risk in Chinese adults, 2013-2023: national cross-sectional surveys
Assistant Professor C. Li (Beijing, CN)
Abstract
Presentation thumbnail
The association of multi-system health status and its longitudinal changes with cardiovascular disease risk: insights from multinational cohorts study
Miss Y. Xin (Beijing, CN)
Abstract
Presentation thumbnail
Uncontrolled cardiometabolic risk factors and risk of cardiac dysfunction in psoriasis: the PSOCADIA study
Miss C. Jansen (Hellerup, DK)
Abstract
Presentation thumbnail
Associations between a body shape index and cardiometabolic risk markers: age- and sex-specific patterns in a Brazilian population
Doctor T. Minari (Sao Paulo, BR)
Abstract
Presentation thumbnail
Cardiovascular risk factor control after implementation of mandatory risk assessment in a tertiary cardiovascular centre
Miss A. Palikuca (Novi Sad, RS)
Abstract

Access the full session

Session thumbnail
Cardiovascular risk assessment

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular-kidney-metabolic syndrome and association with mortality in the UK Biobank prospective cohort study
1 September 2025
thumbnail
Congress Presentation
Inflammatory indexes as predictors of major adverse cardiovascular events in acute myocardial infarction: insights from the INFINITY Study
31 August 2025
thumbnail
Congress Presentation
Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial
26 August 2022
thumbnail
Congress Presentation
Inverse associations of cardiorespiratory fitness with resting inflammation markers are pronounced by metabolic syndrome status in the general population
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources